The Center for Biosimilars® recaps the top stories for the week of September 9, 2019.
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 9, 2019.
Number 5: Genentech has reached an agreement with JHL Biotech in a civil lawsuit related to trade secret theft. Under the agreement, JHL will have to destroy its biosimilar cell lines.
Number 4: The European Patent Office did not grant Alexion its request for 2 patents on Soliris.
Number 3: Celltrion has announced that its trastuzumab biosimilar, Herzuma, has received authorization from Health Canada.
Number 2: Patient organizations for those with inflammatory bowel disease are voicing concern about British Columbia’s plan to transition patients to biosimilars.
Number 1: A new report released Monday by UnitedHealth Group finds that administering specialty drugs outside of hospitals could save $4 billion each year.
Finally, last week, our e-newsletter asked what you think is the greatest challenge facing biosimilars in the United States.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.